Related Experiment Video
Updated: Apr 7, 2026
05:21
Establishment of A Mouse Model of Aqueous Deficiency Dry Eye
Published on: November 1, 2024
1.6K
Omegas and Dry Eye: More Knowledge, More Questions
Milton M Hom1, Penny Asbell, Brendan Barry
1*OD, FAAO †MD, MBA ‡BA Private Practice, Azusa, California (MMH); and Icahn School of Medicine at Mount Sinai, New York, New York (PA, BB).
Summary
Omega-3 and omega-6 fatty acids show promise for dry eye disease (DED), but more high-quality trials are needed. Current evidence is limited, and optimal dosages and treatment plans for omega-3 PUFAs in DED remain unclear.
Area of Science:
- Ophthalmology and Nutritional Science
Background:
- Dry eye disease (DED) is a prevalent condition requiring effective treatments.
- Omega-3 (ω3) and omega-6 (ω6) polyunsaturated fatty acids (PUFAs) play crucial roles in ocular health, with growing research interest.
- The precise mechanisms and therapeutic benefits of ω3 and ω6 PUFAs in DED management are not fully elucidated.
Purpose of the Study:
- To review the current scientific evidence on the efficacy of ω3 and ω6 supplementation for dry eye disease.
- To highlight the need for more robust clinical trials to establish evidence-based treatment guidelines for DED.
Main Methods:
- Literature review of clinical trials and studies published between 2010 and 2015, focusing on ω3 and ω6 supplementation for DED.
- Analysis of the existing evidence regarding the roles of ω3 and ω6 PUFAs in DED pathogenesis and treatment.
Main Results:
- A significant increase in clinical trials investigating ω3 and ω6 supplementation for DED has been observed.
- Despite promising evidence, a lack of high-quality randomized controlled trials hinders the establishment of evidence-based recommendations.
- Variability in dietary intake and lack of consensus on optimal supplementation protocols (dose, composition, duration) complicate treatment strategies.
Conclusions:
- ω3 and ω6 PUFAs hold potential as therapeutic agents for DED.
- Further high-quality research, including large-scale, multi-site studies, is essential to determine optimal usage and confirm efficacy.
- Standardized protocols and objective correlation of blood levels with DED symptom improvement are needed for clinical implementation.
Related Concept Videos
01:22Microbiome of the Eye
47
The human eye has a specialized microbiota that reflects its unique anatomical and immunological environment. This low-biomass microbial community predominantly colonizes the conjunctiva and eyelid margins, playing a vital role in ocular surface homeostasis and defense. Despite its proximity to the richly colonized facial skin, the ocular surface maintains a distinct microbial profile due to continuous mechanical and biochemical defense mechanisms.The conjunctival surface hosts fewer microbial...
47
01:17Accessory Structures of the Eye
4.5K
Optical perception, or vision, is an extraordinary sense dependent on converting light signals received via the ocular organs. These organs, known as eyes, are securely positioned within the bony cavities of the skull, called orbits. The orbits serve a dual purpose: a protective shield for the ocular globes and a stable attachment point for the soft ocular tissues. The eye's external protective mechanisms include the eyelids, which are edged with lashes that act as a barrier against foreign...
4.5K
01:23Ophthalmic Drug Delivery Systems
224
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
224
01:28Angle Closure Glaucoma: Treatment
1.7K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.7K
01:27Open Angle Glaucoma: Treatment
1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
01:25Glaucoma: Overview
1.7K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.7K